Review links bivalirudin with fewer complications in children on ECMO
A pooled analysis found lower odds of several serious outcomes than with unfractionated heparin, but it cannot establish that bivalirudin caused the differences.
Moderate evidenceReviewInterpret with caution
Medical disclaimer: This article summarizes research findings and is for informational purposes only. It is not medical advice.
Editorial illustration — not from the study.
Anticoagulant medicines are used during ECMO because blood clots can block the equipment, while too much anticoagulation can contribute to serious bleeding. This review compared outcomes reported for bivalirudin and unfractionated heparin in children receiving ECMO.
Across the included studies, bivalirudin was associated with lower odds of several complications and with faster achievement of target anticoagulation levels. ECMO duration was longer in the bivalirudin groups, while some outcomes, including circuit clotting, mortality during ECMO, and time in the target range, did not differ significantly. Because the evidence came from previously conducted studies and the abstract does not establish that they were randomized, the results should be interpreted cautiously.
What the review examined
The researchers conducted a systematic review and meta-analysis of studies comparing bivalirudin with unfractionated heparin in pediatric ECMO patients. They searched six medical databases through April 4, 2026, and analyzed 12 studies involving 770 patients using statistical models designed to combine results that may vary between studies.
What the evidence shows
Compared with unfractionated heparin, bivalirudin was associated with lower odds of major bleeding, with an odds ratio of 0.20; systemic thrombosis, or blood clots affecting the body, with an odds ratio of 0.42; neurologic events with an odds ratio of 0.47; and in-hospital mortality with an odds ratio of 0.57. The reported confidence intervals were 0.12–0.32, 0.23–0.75, 0.29–0.78, and 0.41–0.79, respectively. Bivalirudin was also associated with faster achievement of therapeutic targets. ECMO duration was longer with bivalirudin, while the review found no significant difference in circuit thrombosis, mortality while on ECMO, or time within the therapeutic range. These are associations from pooled study data, not proof of cause and effect.
Who this may apply to
These findings may be relevant to children receiving ECMO in settings similar to those represented in the included studies. They do not necessarily apply to adults, children who are not receiving ECMO, or patients treated in different clinical settings. The review compares groups across prior studies and does not provide individualized medical guidance or establish that bivalirudin will produce the same outcomes for every child.
What this could mean
Anticoagulation during pediatric ECMO involves competing risks of bleeding and clotting, so comparisons between commonly used medicines may help identify questions for further research. The findings suggest that bivalirudin may be associated with different outcomes than unfractionated heparin in children receiving ECMO, but they do not establish which medicine is preferable for an individual patient or show that one medicine caused better outcomes.
Limitations & evidence assessment
Only 12 studies and 770 patients were included, and the abstract does not give enough information about the designs, clinical settings, or differences among those studies. The abstract indicates that prospective multicenter studies and randomized trials are still needed, so the pooled results may be affected by limitations of the existing evidence, including possible differences in patient selection and care between treatment groups. Statistical differences were not found for every outcome, and the reason for the longer ECMO duration with bivalirudin is not established. The abstract also does not provide detailed information about follow-up, adverse effects beyond the listed outcomes, or study quality.
Why this evidence level: This is a systematic review and meta-analysis, which combines results from 12 studies involving 770 children. However, the abstract says that prospective multicenter studies and randomized trials are still needed, and it does not provide enough detail to judge the designs and consistency of all included studies.
Evidence levels are editorial estimates derived from study metadata — they are not clinical appraisals.
// Source
The International Journal of Artificial Organs · 2026 · DOI: 10.1177/03913988261481295
Researchers created hydrogel composites that can be reshaped in water by changing the direction of polarized light. The cubes stretched to as much as twice their original side length, and the team made microscopic wells that could fully close.
A study used detailed imaging of the tiny blood vessels at the base of the fingernail to examine cardiovascular health in 104 healthy adults over 80. People with denser, smaller and less winding vessels tended to have more favorable measures of heart function and arterial stiffness.
A study in Nano-Micro Letters finds that isomalt, a sugar-derived additive, improved the operation of alkaline zinc–iron flow batteries. Batteries using the additive cycled for over 500 cycles at 20 mA cm⁻² and reached 87.5% energy efficiency in full-cell tests.
